OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
Ohio ranked No. 1 for business by CNBC
July 10, 2026
Ohio is CNBC’s No. 1 Top State for Business in 2026. The University of Cincinnati helps fuel that success through co-op, innovation, talent development and close collaboration with the state.
UC students organize free health clinic happening July 11-12
July 10, 2026
The University of Cincinnati student chapter of Remote Area Medical is holding its annual free health clinic July 11-12. The clinic is open to adults and children, with no income requirements. Anyone in the area who needs medical, dental or vision care will have a chance to get it for free, with no insurance required.
Is speech-to-text AI really reliable?
July 10, 2026
UC researcher Nelly Elsayed’s study in the International Journal of Medical Informatics reveals key risks in clinical speech-to-text AI and shows why human review is essential.